Bisorcic

Bisorcic (INNTooltip International Nonproprietary Name), also known as N²,N⁵-diacetyl-L-ornithine, is a drug described as a hepatoprotective agent and "psychostimulant" which has been used in France in the treatment of asthenia.^{[2][3][4][5][1]} It is the N²,N⁵-diacetylated derivative of the amino acid L-ornithine.^[6]

Bisorcic

Clinical data
Other names	N2,N5-Diacetyl-L-ornithine; N2,N5-Diacetylornithine; Nα,Nδ-Diacetylornithine
Routes of administration	Oral[1]
Drug class	Hepatoprotective agent; Psychostimulant[2][1]
Identifiers
IUPAC name (2S)-2,5-diacetamidopentanoic acid
CAS Number	39825-23-5
PubChem CID	65977
ChemSpider	59375
UNII	3V77J79MIF
ChEBI	CHEBI:133217
ChEMBL	ChEMBL3989425
CompTox Dashboard (EPA)	DTXSID50960387
ECHA InfoCard	100.049.659
Chemical and physical data
Formula	C9H16N2O4
Molar mass	216.237 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)NCCC[C@@H](C(=O)O)NC(=O)C
InChI InChI=1S/C9H16N2O4/c1-6(12)10-5-3-4-8(9(14)15)11-7(2)13/h8H,3-5H2,1-2H3,(H,10,12)(H,11,13)(H,14,15)/t8-/m0/s1 Key:XUYANFPPYJSBPU-QMMMGPOBSA-N

Bisorcic was first described in the literature in 1973 in a German patent.^[2] The INNTooltip International Nonproprietary Name was designated around 1975.^[7] The drug was marketed in France by Astyl-Gallier in 1987.^[1] It was provided in the form of 200 mg oral capsules and four capsules were taken daily.^[1]

L-Ornithine, as the combination drug L-ornithine L-aspartate (LOLA), has been used in the treatment of hepatic encephalopathy and cirrhosis and is likewise described as hepatoprotective.^[8][9] It is thought to work by participating in the urea cycle and lowering ammonia levels.^[8][9]